Products Risankizumab was approved in the United States and in many countries in 2019 as a solution for injection (Skyrizi). Structure and properties Risankizumab is a humanized IgG1 monoclonal antibody produced by biotechnological methods. Effects Risankizumab (ATC L04AC) has selective immunosuppressive and anti-inflammatory properties. The antibody binds to the p19 subunit of human interleukin-23 (IL-23), … Risankizumab
Products Infliximab is commercially available as a powder for a concentrate for the preparation of an infusion solution (Remicade, biosimilars: Remsima, Inflectra). It has been approved in many countries since 1999. Biosimilars were released in 2015. Structure and properties Infliximab is a chimeric human murine IgG1κ monoclonal antibody with a molecular mass of 149.1 kDa … Infliximab: Drug Effects, Side Effects, Dosage and Uses
Products TNF-α inhibitors are commercially available as injectable and infusion preparations. Infliximab (Remicade) was the first agent from this group to be approved in 1998, and in many countries in 1999. Biosimilars of some representatives are now available. Others will follow in the next few years. This article refers to biologics. Small molecules can also … TNF-Α Inhibitors
Products Guselkumab was approved in the United States and the EU in 2017 and in many countries in 2018 as a solution for injection for subcutaneous use (Tremfya). Structure and properties Guselkumab is an IgG1λ monoclonal antibody produced by biotechnological methods. Effects Guselkumab (ATC L04AC16) has anti-inflammatory and immunosuppressive properties. The effects are due to … Guselkumab
Products Brodalumab was approved in Japan in 2016 (Lumicef) and in the United States and EU in 2017 as a solution for injection (Siliq, Kyntheum). Structure and properties Brodalumab is an IgG2κ monoclonal antibody with a molecular weight of 144 kDa, consisting of 1312 amino acids. It is produced by biotechnological methods. Effects Brodalumab (ATC … Brodalumab
Products Ixekizumab was approved in the United States, the EU, and many countries in 2016 as a solution for injection in a prefilled pen and syringe (Taltz). Structure and properties Ixekizumab is a humanized IgG4 monoclonal antibody with a molecular mass of 146 kDa produced by biotechnological methods. Effects Ixekizumab (ATC L04AC13) has immunosuppressive and … Ixekizumab
Products Adalimumab is commercially available as a solution for injection (Humira). It was approved in the United States in 2002 and in many countries and the EU in 2003. Biosimilars are available in many countries. Structure and properties Adalimumab is a human IgG1 monoclonal antibody against TNF-alpha. It is composed of 1330 amino acids and … Adalimumab Effects and Side Effects
Symptoms Psoriasis is a chronic inflammatory, benign, and noninfectious skin disease. It manifests as symmetrical (bilateral), sharply demarcated, bright red, dry, raised plaques covered by silvery scales. Typically affected areas are the elbows, knees, and scalp. Itching, a burning sensation and pain are other symptoms, and scratching further aggravates the condition. Psoriasis can also affect … Psoriasis Causes and Treatment
Products Apremilast is commercially available in the form of film-coated tablets (Otezla). It was approved in the United States in 2014 and in many countries and the EU in 2015. Structure and properties Apremilast (C22H24N2O7S, Mr = 460.5 g/mol) is a dioxoisoindole acetamide derivative. Effects Apremilast (ATC L04AA32) has immunomodulatory and anti-inflammatory properties. The effects … Apremilast
Products Tildrakizumab was approved as an injectable in the United States and EU in 2018 and in many countries in 2019 (ilumetri). Structure and properties Tildrakizumab is a humanized IgG1/k monoclonal antibody with an approximate molecular mass of 147 kDa. It is produced by biotechnological methods. Effects Tildrakizumab (ATC L04AC17) has immunosuppressive and anti-inflammatory properties. … Tildrakizumab
Products Ustekinumab is commercially available as a solution for injection (Stelara). It was newly approved in the EU in January 2009, in the United States in September 2009, and in many countries in October 2010. In 2017, a concentrate for the preparation of an infusion solution was also approved. This article refers to subcutaneous administration. … Ustekinumab
Products Certolizumab is commercially available as a solution for injection (Cimzia). It has been approved in many countries since 2007. Structure and properties Certolizumab is the Fab’ fragment of a recombinant humanized antibody. It is conjugated to polyethylene glycol (PEG) and is therefore also known as certolizumab pegol. Effects Certolizumab (ATC L04AB05) has selective immunosuppressive … Certolizumab
